JP2023500248A5 - - Google Patents

Info

Publication number
JP2023500248A5
JP2023500248A5 JP2022525129A JP2022525129A JP2023500248A5 JP 2023500248 A5 JP2023500248 A5 JP 2023500248A5 JP 2022525129 A JP2022525129 A JP 2022525129A JP 2022525129 A JP2022525129 A JP 2022525129A JP 2023500248 A5 JP2023500248 A5 JP 2023500248A5
Authority
JP
Japan
Prior art keywords
cancer
seq
epitope
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500248A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2020/015656 external-priority patent/WO2021091359A1/ko
Publication of JP2023500248A publication Critical patent/JP2023500248A/ja
Publication of JP2023500248A5 publication Critical patent/JP2023500248A5/ja
Priority to JP2026077564A priority Critical patent/JP2026119190A/ja
Pending legal-status Critical Current

Links

JP2022525129A 2019-11-08 2020-11-09 制御性t細胞表面抗原のエピトープおよびこれに特異的に結合する抗体 Pending JP2023500248A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026077564A JP2026119190A (ja) 2019-11-08 2026-05-01 制御性t細胞表面抗原のエピトープおよびこれに特異的に結合する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0142251 2019-11-08
KR20190142251 2019-11-08
PCT/KR2020/015656 WO2021091359A1 (ko) 2019-11-08 2020-11-09 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026077564A Division JP2026119190A (ja) 2019-11-08 2026-05-01 制御性t細胞表面抗原のエピトープおよびこれに特異的に結合する抗体

Publications (2)

Publication Number Publication Date
JP2023500248A JP2023500248A (ja) 2023-01-05
JP2023500248A5 true JP2023500248A5 (cg-RX-API-DMAC7.html) 2023-11-16

Family

ID=75848106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525129A Pending JP2023500248A (ja) 2019-11-08 2020-11-09 制御性t細胞表面抗原のエピトープおよびこれに特異的に結合する抗体
JP2026077564A Pending JP2026119190A (ja) 2019-11-08 2026-05-01 制御性t細胞表面抗原のエピトープおよびこれに特異的に結合する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026077564A Pending JP2026119190A (ja) 2019-11-08 2026-05-01 制御性t細胞表面抗原のエピトープおよびこれに特異的に結合する抗体

Country Status (9)

Country Link
US (1) US20250243272A1 (cg-RX-API-DMAC7.html)
EP (1) EP4056586A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023500248A (cg-RX-API-DMAC7.html)
KR (1) KR102488967B1 (cg-RX-API-DMAC7.html)
CN (1) CN114929733A (cg-RX-API-DMAC7.html)
AU (2) AU2020380072B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022008730A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156600A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021091359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020080853A1 (ko) * 2018-10-17 2020-04-23 주식회사 굳티셀 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
KR20230016148A (ko) * 2021-07-16 2023-02-01 주식회사 굳티셀 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
TW202330911A (zh) * 2021-11-24 2023-08-01 日商雷格細胞股份有限公司 人類誘導性控制性t細胞及其製作方法
WO2024155094A1 (ko) * 2023-01-17 2024-07-25 주식회사 굳티셀 조절 t 세포 표면 항원 및 이에 특이적으로 결합하는 항체
WO2024191142A1 (ko) * 2023-03-10 2024-09-19 주식회사 굳티셀 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011066048A1 (en) * 2009-10-22 2011-06-03 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
KR101847523B1 (ko) * 2011-01-24 2018-05-28 연세대학교 산학협력단 조절자 T 세포에 특이적으로 존재하는 새로운 표면단백질 Lrig-1의 용도
DE102016123859B3 (de) * 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
KR20180116924A (ko) * 2017-04-18 2018-10-26 주식회사 굳티셀 면역 세포 표면 단백질의 항원 결정기인 폴리펩티드
EP3613771A4 (en) * 2017-04-18 2021-08-04 Good T Cells, Inc. SPECIFIC LRIG-1 PROTEIN BINDING MOLECULE AND ITS USE
KR20180116925A (ko) * 2017-04-18 2018-10-26 주식회사 굳티셀 암 또는 면역 질환의 예방 또는 치료용 약학 조성물
US20210085785A1 (en) * 2018-02-23 2021-03-25 Truebinding, Inc. Treating cancer by blocking the interaction of vista and its binding partner
KR101959237B1 (ko) * 2018-02-26 2019-03-20 주식회사 굳티셀 조절자 T 세포에 특이적으로 존재하는 새로운 표면단백질 Lrig-1의 용도
KR102194644B1 (ko) * 2018-04-26 2020-12-24 주식회사 굳티셀 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Similar Documents

Publication Publication Date Title
KR101287280B1 (ko) 태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제
ES2377098T3 (es) Moléculas de anticuerpo fv de cadena sencilla biespec�?ficas y métodos de uso de los mismos.
JP2022169589A5 (cg-RX-API-DMAC7.html)
JP2022502371A5 (cg-RX-API-DMAC7.html)
JP2022527635A5 (cg-RX-API-DMAC7.html)
CN110740754A (zh) 一种抗间皮素抗体及其抗体药物缀合物
US20230174660A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer
JP2020519295A5 (cg-RX-API-DMAC7.html)
RU2021130306A (ru) Композиции il-12, нацеленные на edb
JP2023040169A5 (cg-RX-API-DMAC7.html)
JP2023538422A5 (cg-RX-API-DMAC7.html)
JP2014528714A5 (cg-RX-API-DMAC7.html)
JP2020521478A5 (cg-RX-API-DMAC7.html)
CN101663317A (zh) 胰高血糖素样蛋白-1受体glp-1r激动剂化合物
US20170247465A1 (en) Combination therapy for treatment of cancer
CA2560278A1 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
JP2020509737A5 (cg-RX-API-DMAC7.html)
CN107708731A (zh) 治疗癌症的组合疗法
JP2021508694A (ja) 抗sez6抗体薬物コンジュゲート及び使用方法
JP2017043620A (ja) 溶解性ペプチド−Her2/neu(ヒト上皮成長因子レセプター2)リガンド結合体およびその使用方法
HRP20161449T1 (hr) Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena
JPS63503144A (ja) 葉酸類縁体のアミン誘導体
EP4056586A1 (en) Epitope of regulatory t cell surface antigen, and antibody specifically binding thereto
Tan et al. Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities
JP2024519904A5 (cg-RX-API-DMAC7.html)